What is Mycoplasma Testing in Clinical Settings?

Mycoplasma testing identifies active or recent infections caused by mycoplasma bacteria, a common cause of respiratory and other infections. The most prevalent type, Mycoplasma pneumoniae, primarily affects the upper respiratory tract and is often tested via blood samples for antibodies. Other infections may require diverse samples, including sputum, joint fluid, body fluids, tissue, or genital swabs. Testing techniques encompass microbial culture (direct assay), polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), DNA staining (indirect assay), and enzymatic methods. These tests are critical for detecting contamination in cell cultures used in biopharmaceuticals, ensuring product safety, and diagnosing clinical infections across respiratory, urogenital, gastrointestinal, musculoskeletal, cardiovascular, and other disease areas. Accurate testing prevents complications from undetected mycoplasma, which can lead to severe respiratory illnesses or contaminate biotherapeutics.

Market Overview

According to Data Bridge Market Research, the global mycoplasma testing in clinical market was valued at USD 295.06 million in 2022 and is projected to reach USD 526.23 million by 2030, growing at a CAGR of 7.5% during the forecast period of 2023–2030. Growth is propelled by increasing R&D investments in biopharmaceuticals, rising concerns over cell culture contamination, and heightened demand for reliable diagnostics amid respiratory disease burdens.

Market Segmentation

The market is segmented as follows:

• By Products: Kits and Reagents (dominant due to repeated purchases), Instruments, Services.
• By Technique: Microbial Culture Techniques/Direct Assay, Polymerase Chain Reaction, ELISA, DNA Staining/Indirect Assay, Enzymatic Methods.
• By Application: Cell Line Testing, Virus Testing.
• By Disease Area: Respiratory, Urogenital, Gastrointestinal, Musculoskeletal, Cardiovascular, Others.
• By End User: Diagnostic Laboratories, Hospitals.

Kits and reagents lead in consumables, while PCR techniques gain traction for sensitivity and speed.

Key Market Drivers

• Substantial R&D investments by pharmaceutical giants, such as Bristol-Myers Squibb and Merck KGaA's facility expansions, focusing on efficient testing tools.
• Growing concerns about biological contamination in cell cultures, classified as chemical or biological, necessitating robust mycoplasma detection.
• Rising prevalence of respiratory illnesses, contributing to higher diagnostic demand.

Restraints and Challenges

• High costs of specialized instruments, limiting accessibility in resource-constrained settings.
• Time-consuming and laborious detection processes, delaying results and increasing operational complexity.
  
  Get More Details :
  https://www.databridgemarketresearch.com/reports/global-mycoplasma-testing-in-clinical-market

Opportunities

• Globalization of clinical trials, leveraging cost efficiencies, patient recruitment ease, and less stringent regulations in outsourcing to CROs, CDMOs, and CMOs.
• Innovative product launches and investments in advanced, rapid testing solutions for biopharmaceutical safety.

Regional Insights

• North America dominates the market, driven by repeated consumable purchases for cell culture detection and advanced healthcare infrastructure.
• Asia-Pacific is expected to grow at the highest rate, fueled by increasing demand for effective mycoplasma testing and expanding biopharmaceutical sectors.

Other regions, including Europe, Middle East & Africa, and South America, show varied growth influenced by local R&D and regulatory environments.

Major Market Players

Key companies include:

• AB ANALITICA s.r.l.
• BIOMÉRIEUX
• ELITechGroup
• Liofilchem S.r.l.
• Agilent Technologies, Inc.
• PromoCell GmbH
• F. Hoffmann-La Roche Ltd
• OSANG Healthcare
• Sacace Biotechnologies Srl
• Lonza
• Merck KGaA
• Seegene Inc.
• Clongen Laboratories, LLC
• Bio-Rad Laboratories, Inc.
• Charles River Laboratories
• Bionique Testing Laboratories LLC
• ZEAKON Diagnostics

Recent developments include Liofilchem's AF Genital System launch and BioMérieux's BioFire Mycoplasma Test for biopharmaceuticals.

Conclusion

The global mycoplasma testing in clinical market is set for steady growth through 2030, supported by biopharmaceutical R&D, contamination concerns, and diagnostic advancements. With a projected value of USD 526.23 million, North America leads, while Asia-Pacific offers rapid expansion. Opportunities in global trials and innovations will address cost and process challenges, enhancing infection detection and biotherapeutic safety worldwide.

This summary is based on publicly available insights from the Data Bridge Market Research report overview as of late 2025. For detailed quantitative forecasts, financials, and custom analysis, refer to the full report at the original source.

Browse More Reports:

Asia-Pacific Medical Device Reprocessing Market
Europe Busbar Market
Middle East and Africa Busbar Market
Asia-Pacific Busbar Market
North America Busbar Market
North America Anti-Friction Coatings Market
Europe Anti-Friction Coatings Market
Asia-Pacific Anti-Friction Coatings Market
Middle East and Africa Anti-Friction Coatings Market
North America Automated Liquid Handling Market
Asia-Pacific Automated Liquid Handling Market
Europe Automated Liquid Handling Market
Asia-Pacific Digital Forensics Market
Europe Functional Mushroom Market
Asia-Pacific Functional Mushroom Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- corporatesales@databridgemarketresearch.com